Is hormonal activation during exercise useful for risk stratification in patients with moderate congestive heart

Pascal de Groote1, Benoît Soudan, Nicolas Lamblin

  • 1TOP Service de Cardiologie C, Hôpital Cardiologique, Lille Cedex, France. pdegroote@chru-lille.fr

American Heart Journal
|August 17, 2004
PubMed

Insights

B-type natriuretic peptide (BNP) at rest, not peak exercise, predicts survival in moderate heart failure patients. Exercise levels of BNP, ANP, and norepinephrine did not improve risk stratification. BNP at rest is a key survival predictor.

Area of Science:

  • Cardiology
  • Exercise Physiology
  • Biomarkers

Background:

  • Previous research identified A-type natriuretic peptide (ANP) at peak exercise as a cardiac survival predictor.
  • No data existed on the predictive value of B-type natriuretic peptide (BNP) at peak exercise.

Purpose of the Study:

  • To investigate the predictive value of natriuretic peptides (ANP and BNP) and norepinephrine at rest and peak exercise for cardiac survival in stable congestive heart failure (CHF) patients.
  • To determine if exercise levels of these biomarkers improve risk stratification beyond established predictors.

Main Methods:

  • 150 stable CHF patients underwent echocardiography and cardiopulmonary exercise testing.
  • Plasma levels of ANP, BNP, and norepinephrine were measured at rest and peak exercise.
  • Patients were followed for a median of 1171 days for cardiac-related deaths.

Main Results:

  • Exercise significantly increased plasma levels of ANP, BNP, and norepinephrine.
  • Independent predictors of cardiac survival included percent of maximal predicted oxygen consumption, BNP at rest, and left atrial diameter.
  • Plasma levels of ANP, BNP, and norepinephrine measured at peak exercise did not improve risk stratification.

Conclusions:

  • Peak exercise levels of ANP, BNP, and norepinephrine are not independent predictors of cardiac survival in moderate CHF.
  • BNP at rest, along with maximal oxygen consumption and left atrial diameter, is an independent predictor of survival in this patient group.
  • BNP at rest offers valuable prognostic information for CHF patients with a low risk of cardiac events.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...